Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $39.99 | $8.00/mg | In stock | Jul 8 |
| vial | 10mg | $64.99 | $6.50/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| OR-LPTB10-326-B5 | Apr 2026 | 99.0% | Ethos Analytics | Endotoxin, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. TB-500 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does OROS Research sell TB-500?
Yes — OROS Research currently lists TB-500 in 2 variants starting at $64.99 ($6.50/mg).
Is OROS Research's TB-500 third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for OROS Research's TB-500, with the most recent showing 99.0% purity. OROS Research holds an overall trust grade of A (92/100) across all 44 COAs on file.
What is OROS Research's trust grade for TB-500?
OROS Research has an overall Disclosed Labs trust grade of A (92/100), computed from 44 COAs across all peptides. The most recent TB-500 COA was issued by Ethos Analytics.
Where is the cheapest TB-500?
As of the latest data, Peptide Supply Co. offers TB-500 at $3.40/mg — compare with OROS Research's listing at $6.50/mg. See the full TB-500 price comparison.
Is TB-500 legal to buy?
TB-500 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs